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a b s t r a c t
Dosage compensation (DC) equalizes X-linked gene expression between sexes. In Caenorhabditis elegans,
the dosage compensation complex (DCC) localizes to both X chromosomes in hermaphrodites and
downregulates gene expression 2-fold. The DCC ﬁrst localizes to hermaphrodite X chromosomes at the
30-cell stage, coincident with a developmental transition from plasticity to differentiation. To test
whether DC onset is linked to loss of developmental plasticity, we established a timeline for the
accumulation of DC-mediated chromatin features on X (depletion of histone H4 lysine 16 acetylation
(H4K16ac) and enrichment of H4K20 monomethylation (H4K20me1)) in both wild type and devel-
opmentally delayed embryos. Surprisingly, we found that H4K16ac is depleted from the X even before
the 30-cell stage in a DCC-independent manner. This depletion requires the activities of MES-2, MES-3,
and MES-6 (a complex similar to the Polycomb Repressive Complex 2), and MES-4. By contrast,
H4K20me1 becomes enriched on X chromosomes several cell cycles after DCC localization to the X,
suggesting that it is a late mark in DC. MES-2 also promotes differentiation, and mes-2 mutant embryos
exhibit prolonged developmental plasticity. Consistent with the hypothesis that the onset of DC is linked
to differentiation, DCC localization and H4K20me1 accumulation on the X chromosomes are delayed in
mes mutant hermaphrodite embryos. Furthermore, the onset of hermaphrodite-speciﬁc transcription of
sdc-2 (which triggers DC) is delayed in mes-2 mutants. We propose that as embryonic blastomeres lose
their developmental plasticity, hermaphrodite X chromosomes transition from a MES protein-regulated
state to DCC-mediated repression.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Sex chromosomes present two copy number problems. One is
that the heterogametic sex (XY or XO) is monosomic for the X
chromosome, which carries many genes essential for development
and viability. A second problem is the difference in sex chromo-
some dosage between the sexes (XX vs. XY or XO). A specialized
gene regulatory process called dosage compensation (DC) balances
expression between the X chromosome and diploid autosomes in
the heterogametic sex and equalizes X chromosome expression
between the sexes.
The mechanisms of DC in mammals, ﬂies, and worms differ.
Male XY ﬂies upregulate their single X chromosome 2-fold
(Conrad and Akhtar, 2011). Upregulation of the male X chromo-
some balances X-linked gene expression to autosomal levels and
to female X-linked gene expression. Several studies suggested that
the X chromosomes are upregulated in a non-sex-speciﬁc manner
in mammals and worms (Deng et al., 2011, 2013; Gupta et al.,
2006; Kharchenko et al., 2011; Lin et al., 2007, 2011; Nguyen and
Disteche, 2006). This process balances expression of the X chro-
mosome to diploid autosomal levels in males, but causes hyper-
expression of the X in females/hermaphrodites. To combat
hyperexpression of the X chromosomes, mammalian females
randomly inactivate one of their two X chromosomes (Barakat
and Gribnau, 2012), while hermaphrodite worms downregulate
both X chromosomes 2-fold (Csankovszki et al., 2009b). Despite
the differences in mechanisms of DC, the outcome is similar
– balanced expression between the autosomes and sex chromo-
somes and equalized expression between the sexes.
While the DC machineries used by mammals, ﬂies, and worms
differ, changes in chromatin structure are a common feature of
dosage-compensated chromosomes. In female mammals, the non-
coding RNA XIST/Xist triggers establishment of the silent chroma-
tin state on the inactive chromosome in a stepwise manner
(Morey and Avner, 2011; Nora and Heard, 2010). Initially, RNA
Polymerase II and marks of active chromatin, including acetylation
of histone H4 lysine 16 (H4K16ac), are excluded from the inactive
X. The Polycomb Repressive Complex 2 (PRC2) establishes repres-
sive histone H3 lysine 27 (H3K27) methylation which then recruits
PRC1 to ubiquitinate H2A lysine 119. Later modiﬁcations that help
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to solidify the silent state include incorporation of the histone
variant macroH2A and DNA methylation. DC in male ﬂies is
achieved through the action of the Male-Speciﬁc Lethal (MSL)
complex (Conrad and Akhtar, 2011). The MSL complex speciﬁcally
binds the male X chromosome, concentrates MOF acetyltransfer-
ase activity, and leads to increased H4K16ac on the X (Akhtar and
Becker, 2000; Smith et al., 2000). In Caenorhabditis elegans
hermaphrodites, the dosage compensation complex (DCC) speci-
ﬁcally binds both X chromosomes. Five subunits of the DCC, MIX-1,
DPY-27, DPY-28, CAPG-1, and DPY-26, form a subcomplex (Con-
densin IDC) that resembles mitotic and meiotic condensin com-
plexes (Chuang et al., 1994; Csankovszki et al., 2009a; Lieb et al.,
1996, 1998; Tsai et al., 2008). Dependent on the activity of the DCC
and the HDAC SIR-2.1, H4K16ac is depleted from hermaphrodite X
chromosomes (Wells et al., 2012a, b). In addition, the repressive
chromatin mark, monomethylation of histone H4 lysine 20
(H4K20me1) is enriched on the X chromosomes in a DCC-
dependent manner (Vielle et al., 2012; Wells et al., 2012b). The
histone H2A variant HTZ-1 contributes to DCC-mediated repres-
sion indirectly, by regulating DCC localization (Petty et al., 2009,
2011). Therefore, in all three systems, the dosage-compensated X
chromosomes have unique chromatin features distinct from other
chromosomes.
In mammals, the onset of dosage compensation correlates with
cellular differentiation. Undifferentiated pluripotent cells have
some level of X upregulation, but full upregulation in males and
X chromosome inactivation in females occurs upon differentiation
(Lin et al., 2007). Linking the onset of X inactivation to the loss of
pluripotency is achieved by direct regulation of Xist and its
antisense counterpart Tsix by pluripotency regulators. The plur-
ipotency factors Oct4, Nanog, and Sox2 bind to intron 1 in Xist,
repressing expression of Xist in undifferentiated embryonic stem
cells (Navarro et al., 2008). As differentiation proceeds, these
factors are lost, allowing Xist expression and inactivation of the
X chromosome. Three other pluripotency factors, Rex1, KLF4, and
c-Myc, positively regulate Tsix, a non-coding RNA repressor of Xist
(Navarro et al., 2010). While deletion of intron 1 is not sufﬁcient to
cause increased Xist expression (Barakat et al., 2011), combining
deletion of intron 1 with removal of Tsix is sufﬁcient, at least in a
transgenic context (Nesterova et al., 2011).
Whether loss of pluripotency and DC onset are linked in ﬂies
and worms, as in mammals, is unclear. The timing of DCC
localization to the X chromosome is coincident with differentia-
tion in ﬂies and worms. In Drosophila males, the MSL proteins
localize to the X chromosome at the late blastoderm/early gastrula
stage, when the three germ layers are speciﬁed (Franke et al.,
1996; Rastelli et al., 1995). In C. elegans hermaphrodites as well,
the DCC begins to load onto the X chromosomes around the
30-cell stage (Chuang et al., 1994; Dawes et al., 1999), effectively
coincident with the beginning of gastrulation at the 26-cell stage
(Sulston et al., 1983). Somatic blastomeres lose their developmen-
tal plasticity soon after, by the 100-cell stage, and can no longer be
reprogrammed by forced expression of developmental transcrip-
tion factors (Fukushige and Krause, 2005; Gilleard and McGhee,
2001; Horner et al., 1998; Joshi et al., 2010; Quintin et al., 2001;
Zhu et al., 1998).
The PRC2 complex has emerged as a regulator of pluripotency
and differentiation in both mammals and C. elegans. In mouse and
human ES cells, the PRC2 complex represses lineage-speciﬁc
developmental regulators, suggesting that PRC2 is required to
maintain pluripotency (Boyer et al., 2006; Lee et al., 2006).
However, other studies indicate that PRC2 components are also
required to repress pluripotency factors during differentiation, and
stem cells deﬁcient in various PRC2 subunits exhibit a reduced
capacity to differentiate (Landeira et al., 2010; Li et al., 2010; Pasini
et al., 2010; Peng et al., 2009; Shen et al., 2009). Consistent with
a requirement to repress developmental regulators, in PRC2-
deﬁcient C. elegans, germ cells can be converted into neuronal or
muscle cell types upon expression of ectopic regulators (Patel
et al., 2012). On the other hand, C. elegans embryos deﬁcient in
MES-2 (homolog of E(z)/EZH2) show delayed differentiation
(Yuzyuk et al., 2009). Derepression of developmental regulators,
combined with faulty repression of pluripotency factors, may lead
to an overall phenotype of aberrant differentiation.
The PRC2 complex in C. elegans plays an additional role. The X
chromosome is silenced in both XX hermaphrodite and XO male
germ lines in a process unrelated to dosage compensation in the
soma. Germline silencing of the X chromosome depends on a
PRC2-like complex composed of MES-2,3, and 6, which
accumulates H3K27me3 on the X (Bender et al., 2004; Capowski
et al., 1991; Garvin et al., 1998; Holdeman et al., 1998), as well as
MES-4, an autosomally enriched histone H3 lysine 36 (H3K36)
methyltransferase that repels repression by MES-2/3/6 from the
autosomes (Bender et al., 2004; Gaydos et al., 2012). At least some
of the germline modiﬁcations related to MES protein function are
maintained in the early embryo, inﬂuencing the chromatin state of
the X chromosome (Arico et al., 2011; Furuhashi et al., 2010;
Rechtsteiner et al., 2010).
To determine whether the onset of dosage compensation is
linked to the loss of pluripotency in C. elegans, we ﬁrst established
a timeline for the appearance of DCC-mediated chromatin changes
in embryos. We showed that these chromatin features accumulate
gradually. Dosage-compensated X chromosomes have reduced
levels of H4K16ac compared to autosomes even before the DCC
localizes to the X, due the activity of the MES proteins. On the
other hand, enrichment of H4K20me1 is a late event in the
establishment of DC. DCC localization, enrichment of H4K20me1,
and expression of the DC trigger gene SDC-2 are all delayed in mes
mutant embryos, indicating that the onset of DC is linked to the
loss of plasticity and suggesting that coupling DC onset to loss of
pluripotency may be universal.
Materials and methods
Strains, alleles, and RNA interference
All strains were maintained as described (Brenner, 1974).
Strains include: N2 Bristol strain (wild type); TY4403 him-8
(e1489) IV; SS186 mes-2(bn11) unc-4(e120)/mnC1 dpy-10(e128)
unc-52(e444) II; SS222 mes-3(bn21) I; VC1874 mes-4(ok2326)
V/nT1[qIs51] (IV;V); TY3936 dpy-21(e428); and TY4161 sdc-1
(y415) X. Male embryos were obtained from him-8(e1489) her-
maphrodites. Mutations in him-8 cause X chromosome nondis-
junction in meiosis and result in 38% of progeny being XO males.
Male embryos were identiﬁed by the presence of only one X
chromosome. Feeding RNAi for capg-1, dpy-26, dpy-28, mes-3, and
mes-6 was performed with the Ahringer laboratory RNAi feeding
library (Kamath and Ahringer, 2003).
Immunostaining
Gravid hermaphrodites were picked into 1 sperm salts
(50 mM PIPES pH7, 25 mM KCl, 1 mM MgSO4, 45 mM NaCl,
2 mM CaCl2) on positively charged slides. Embryos were released
by cutting at the vulva. Paraformaldehyde was added to a ﬁnal
concentration of 2%, and then the sample was covered with a
coverslip. During a 5 min incubation at room temperature, excess
liquid was wicked from the slide until adults ﬂattened. Slides were
frozen on dry ice for at least 10 min. The coverslip was removed,
and the slides were immersed in 20 1C methanol for 10 min.
Slides stained with anti-MES-4 were ﬁxed in 20 1C methanol for
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2 min, then in 20 1C acetone for 2 min. Immunostaining was
performed as described previously, (Collette et al., 2011) for Fig. S5
and (Csankovszki et al., 2009a) for all others.
Polyclonal rabbit anti-DPY-27 and rat anti-CAPG-1 antibodies
(Csankovszki et al., 2009a) were used at 1:100 and 1:50 dilutions,
respectively. Commercially available polyclonal rabbit antibodies
used for immunoﬂuorescence were the following: anti-H3K4me2
(Millipore 07-030; 1:250 dilution), anti-H3K36me2 (Abcam
ab9049; 1:500), anti-H4K16ac (Millipore 07-329; 1:200), anti-
H4K20me1 (Abcam ab9051; 1:200 for Figs. S5 and 1:500 all other
ﬁgures), and anti-MES-4 (Novus 29400002; 1:500). Direct labeling
of rabbit primary antibodies with Alexa Fluor 488 or Alexa Fluor
555 was performed using the Zenon Rabbit IgG kit (Invitrogen),
following the manufacturer's protocol. Secondary antibodies were
from Jackson ImmunoResearch.
Immunoﬂuorescence in situ hybridization (immuno-FISH)
Immunostaining for combined IF and ﬂuorescent in situ hybri-
dization was performed as described above. After incubation in the
secondary antibody, slides were washed in PBS-0.1% Triton X-100
three times (10 min each), ﬁxed for 10 min in 4% paraformalde-
hyde. Slides were dehydrated through an ethanol series (70%, 80%,
and 95% ethanol for 5 min each). Next, slides were incubated three
times for 5 min each in 2 SSC-T (0.3 M NaCl, 30 mM
Na3C6H5O7, and 0.1% Tween-20) and then in 2 SSC-T with
increasing concentrations of formamide (5%, 10%, 25%, and 50%) for
10 min each. The slides were kept in a second wash of 2 SSC-T
with 50% formamide for 1 h at 37 1C. The Xpaint probe was
prepared as described previously (Csankovszki et al., 2004), and
10 ml of probe was added to the slide. The samples were covered
with a coverslip, placed on a 95 1C heat block for 3 min, and slowly
cooled to 37 1C for an overnight incubation. The following washing
regime was used: two 30 min washes at 37 1C in 2 SSC-T
with 50% formamide, 10 min washes at room temperature in 2
SSC-T with decreasing formamide (25%, 10%, and 5%), and three
10 min washes in 2 SSC-T. DAPI was included in the second 2
SSC-T wash. Slides were mounted with Vectashield (Vector
Laboratories).
Microscopy
Images were captured with a Hamamatsu Orca-Erga close-
coupled-device (CCD) camera mounted on an Olympus BX61
motorized Z-drive microscope using a 60 APO oil immersion
Fig. 1. Acetylated H4K16 is depleted from the X chromosomes during all stages of hermaphrodite development. Antibody staining of H4K16ac (green) in wild type
hermaphrodite embryos. The X chromosomes were identiﬁed by a lack of autosomal MES-4 (red, top panels) staining in young embryos or by the presence of the DCC
component CAPG-1 (red, bottom panels) in older embryos. DAPI (blue) labels DNA. Grayscale images of H4K16ac and DAPI are shown for clarity. DIC images of staged
embryos are shown (left column), and representative stained nuclei from each stage are shown. In all stages, less H4K16ac is present on the X chromosomes than the
autosomes. For clarity, the X chromosomes are outlined with a dashed line in the merged and MES-4 images and indicated with an arrow in the grayscale H4K16ac images.
Note that in the 2-cell embryo, one X chromosome (arrow) has reduced H4K16ac, while H4K16ac on the other X chromosome (arrowhead) resembles the autosomes. Scale
bars equal 10 mm (whole embryo images) and 1 mm (nuclei).
L.M. Custer et al. / Developmental Biology 385 (2014) 279–290 281
objective. Projection images were generated from optical sections
with Z spacing of 0.2 mm.
Quantiﬁcation
Slides of N2, mes-2, and mes-4 embryos stained with DPY-27 or
H4K20me1 were screened in a blinded fashion. All embryos on the
slide between the 24- and 100-cell stage and the bean and 2-fold
stage were counted on the DPY-27 and H4K20me1 stained slides,
respectively. Embryos were classiﬁed into four categories based on
the localization of staining of DPY-27 or H4K20me1 in the nucleus.
These categories were the following: no enrichment on X (or
uniform staining across the nucleus for H4K20me1), enrichment
on X in approximately 25% of cells in the embryo, enrichment on X
in 50 to 75% of cells in the embryo, or enrichment on X in 490% of
cells in the embryo. A chi-squared goodness of ﬁt test was
performed between N2 and each mes mutant for each develop-
mental stage. The null hypothesis considered that the fraction of
embryos in a category should be the same between wild type and
mutant embryos. An expected table of counts was generated by
multiplying the total number of embryos counted per stage for
each genotype by the total number of wild type and mutant
embryos in a given category and dividing by the total number
of wild type and mutant embryos in all categories. The values
for each genotype at a particular stage were summed. When
calculating the p-value, three degrees of freedom were considered
in Fig. 6 (four categories), and two degrees of freedom in Fig. S5
(three categories).
Results
Establishment of dosage-compensated chromatin during development
Previous studies revealed that DC on the hermaphrodite X
chromosomes leads to depletion of H4K16ac and enrichment of
H4K20me1 (Vielle et al., 2012; Wells et al., 2012b). Based on this
knowledge, we hypothesized that H4K16ac would not be depleted
from the X chromosomes prior to DCC loading at the 30-cell stage
and that enrichment of H4K20me1 would occur shortly after DCC
localization to the X chromosomes.
To test the ﬁrst prediction, we examined H4K16ac levels at
all developmental stages in wild type hermaphrodite embryos.
We identiﬁed the X chromosomes in embryos younger than the
100-cell stage by the absence of either H3K36me2 or MES-4
(the H3K36me2 methyltransferase), both of which are enriched
on autosomes (Bender et al., 2006; Fong et al., 2002). In embryos
older than the 50-cell stage, we identiﬁed the X chromosomes by
labeling the DCC component CAPG-1 (Csankovszki et al., 2009a).
Contrary to our expectation, we found that the X chromosomes are
Fig. 2. H4K20me1 enrichment on the X chromosomes of hermaphrodite embryos occurs at the comma stage. Antibody staining of H4K20me1 (green), H3K36me2 (red) to
label autosomes, the DCC component CAPG-1 (red) to label the X chromosomes, and DAPI (blue) to label DNA in wild type hermaphrodite embryos. (A) Projection images
through the center z-slices of embryos stained with H4K20me1 and DAPI. (B) Representative stained nuclei from each stage shown in A. In 4- to 100-cell embryos,
H4K20me1 is distributed evenly between the X chromosomes (outlined with dashed line) and autosomes. Variability in levels of H4K20me1 among nuclei in embryos
younger than the bean stage is due to the cells being in different stages of the cell cycle. At the bean stage, H4K20me1 begins to be enriched on the X chromosomes in some
nuclei. By the comma and 2-fold stages, H4K20me1 is enriched on the X chromosomes (labeled with CAPG-1) in most or all nuclei. Scale bars equal 10 mm (whole embryo
images) and 1 mm (nuclei).
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depleted of H4K16ac compared to autosomes during all stages of
embryonic development. Depletion was already evident in 1- and
2-cell embryos, continued in mid-stage embryos both before and
after DCC association, and during stages of morphogenesis and
elongation (bean, comma, and 2-fold stage) (Fig. 1 and data not
shown).
The sperm and oocyte-derived X chromosomes have different
chromatin states, until approximately the 14-cell stage due to
imprinted chromatin assembly on the sperm-derived X (Bean
et al., 2004). Consistent with this imprint, we observed different
levels of H4K16ac on the Xs in 1- and 2-cell embryos (Figs. 1 and
S1). Using antibody staining to H3K4me2 to label all chromosomes
but the sperm-derived X chromosome (Xp) in self-fertilized
hermaphrodites (Bean et al., 2004), we identiﬁed the Xp as the
X chromosome with very low levels of H4K16ac in both 1- and
2-cell embryos (Fig. S1), while acetylation levels on the oocyte-
derived X (Xm) were similar to autosomes. H4K16ac is absent from
the X chromosome throughout spermatogenesis, but it marks
the X chromosome in late stages of oogenesis (Kelly et al., 2002).
Fig. 3. Histone H4 modiﬁcations on the male X chromosome. (A) and (B) H4K16ac
(green) is depleted from the X chromosome (outlined with dashed line) in male
him-8(e1489) embryos until the 60-cell stage. The X chromosome in male embryos
was identiﬁed as the one chromosome per nucleus that did not have MES-4 (red)
autosomal staining (A). After the 60-cell stage, H4K16ac levels on the male X are
equivalent to autosomal levels (B). The embryos were identiﬁed as male by the
presence of only one X territory, marked with Xpaint FISH, in every nucleus.
(C) H4K20me1 levels are uniform between the X chromosome and autosomes in
young male embryos. This modiﬁcation does not become enriched on the male X
chromosome at late morphogenesis stages. Scale bars equal 1 mm.
Fig. 4. Prior to its localization to the X chromosomes, the DCC does not regulate
H4K16ac levels. Antibody staining of H4K16ac (green), H3K36me2 (red) to label
autosomes, and DAPI (blue) to label DNA in mutant hermaphrodite embryos.
H4K16ac is reduced on the X chromosomes (outlined with a dashed line) compared
to autosomes in 4- to 16-cell hermaphrodite embryos from wild type, sdc-1(y415)
mutant, and capg-1, dpy-26, and dpy-28 RNAi-treated adults. Levels of H4K16ac are
similar between the X chromosomes and autosomes in dpy-21(e428) mutant
embryos. Scale bars equal 1 mm.
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Our results demonstrate that 1- and 2-cell embryos maintain
H4K16ac levels found on X chromosomes immediately prior to
fertilization. By the 4-cell stage, both X chromosomes appear
depleted of H4K16ac, consistent with the loss of oocyte-incorpo-
rated H4K16ac after replication and cell division.
To test the prediction that the timing of H4K20me1 enrichment
correlates with DCC binding, we assessed H4K20me1 levels in
different stage embryos (Fig. 2). Consistent with a previous report
(Vielle et al., 2012), we observed higher levels of H4K20me1 signal
intensity in mitosis than in interphase nuclei, but the H4K20me1
signal was evenly distributed within nuclei in early and mid-
embryogenesis. At the 100-cell stage, the DCC is localized to the X
chromosomes, but H4K20me1 levels remain uniform between the
X and autosomes. Enrichment of H4K20me1 on the hermaphrodite
X chromosomes begins at the bean stage. By the comma stage,
almost all nuclei in the embryo show enrichment of H4K20me1 on
the X chromosomes. At this stage and beyond, all, or almost all,
nuclei have striking enrichment of H4K20me1 that colocalizes
with the DCC (CAPG-1) (Fig. 2B), as reported previously (Vielle
et al., 2012). Therefore, this change in chromatin structure occurs
signiﬁcantly later in development than the binding of the DCC to
the X chromosomes.
Chromatin modiﬁcations of the embryonic male X chromosome
Because the DCC does not repress the X chromosome in males,
we hypothesized that H4K16ac on the male X chromosome would
equal autosomal levels. Because the male X is thought to be
upregulated compared to autosomes, one possibility is that
H4K16ac levels would be even higher than on autosomes. How-
ever, we found that like hermaphrodite embryos, H4K16ac is
depleted from the single male X chromosome in early embryos
through the 50-cell stage, and the staining intensity becomes
uniform across the nucleus by the 100-cell stage (Fig. 3). This
result suggests that the H4K16ac on the X chromosome is
regulated in the same manner in young hermaphrodite and male
embryos and is unlikely to be regulated by the DCC.
Second, we predicted that H4K20me1 levels would be uniform
in male embryos, resembling adult males (Wells et al., 2012a, b).
We tested this hypothesis by analyzing H4K20me1 levels in male
embryos by IF. At all stages of male embryogenesis, levels of
H4K20me1 are uniform across the nucleus (Fig. 3C). We never
observe enrichment of H4K20me1 on the male X chromosome.
Thus, the enrichment of H4K20me1 is speciﬁc to dosage-
compensated hermaphrodite X chromosomes.
Histone H4 chromatin state in early embryos is regulated by the MES
proteins
In older hermaphrodite embryos and adults, both depletion
of H4K16ac and enrichment of H4K20me1 on the X chromosomes
are regulated by the DCC (Figs. S2 and S3) (Vielle et al., 2012; Wells
et al., 2012b). Depletion of H4K16ac, but not enrichment of
H4K20me1, is also observed in both young male embryos and
in hermaphrodite embryos prior to DCC loading onto the X.
We anticipated that this depletion of H4K16ac would not be
regulated by the DCC. Indeed, mutations in the DCC subunit sdc-1
and RNAi against other subunits of the DCC, including capg-1, dpy-26,
and dpy-28, do not affect depletion of H4K16ac on the X chromo-
somes in young hermaphrodite embryos (Fig. 4). In these embryos,
the level of H4K16ac on the X chromosomes is reduced compared
to the autosomes, resembling wild type and vector RNAi controls.
Fig. 5. X chromosome H4K16ac levels are restored to autosomal levels in mesmutants. (A) Nuclei from 8- to 16-cell embryos stained with anti-H4K16ac (green). Xpaint FISH
(red) labels the X chromosomes. In mes-2(bn11), mes-3(bn21), and mes-4(ok2326) MZ mutant and mes-6 RNAi-depleted hermaphrodite embryos, H4K16ac levels are
equivalent between the X chromosomes (outlined with dashed line) and autosomes. (B) Immunoﬂuorescent staining of H4K16ac (green) and CAPG-1 (X chromosomes, red).
At the 2-fold stage, H4K16ac levels are depleted on the X chromosomes in mes-2(bn11) and mes-4(ok2326) MZ embryos and mes-3 and mes-6 RNAi-depleted embryos.
Scale bars equal 1 mm.
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By contrast, in dpy-21(e428) mutant embryos, H4K16ac levels on the
X chromosomes are similar to those on the autosomes, suggesting a
possible DCC-independent role for dpy-21 (Fig. 4, bottom panels).
We next considered the possibility that depletion of H4K16ac
on the X chromosomes of young embryos is a consequence of MES
protein function. The MES proteins silence X chromosome genes in
the germline. These same proteins (MES-2, 3, 4, and 6) are present
in the nuclei of all cells in young embryos and later become
restricted to germline precursors (Fong et al., 2002; Holdeman
et al., 1998; Korf et al., 1998; Xu et al., 2001). To test the hypothesis
that MES function is required for the depletion of H4K16ac on the
X, we examined young mes mutant embryos by IF. We identiﬁed
Fig. 6. The timing of DC onset is delayed in mes-2(bn11) and mes-4(ok2326) mutants. (A) At the 50-cell stage, the DCC component DPY-27 localizes to the X chromosomes in
most cells in N2 embryos, but only a few cells in ames-2(bn11) MZ and ames-4(ok2316) MZ embryo. At the 100-cell stage, DPY-27 localizes to the X chromosomes in
all cells in all three genotypes. (B) H4K20me1 becomes restricted to the X chromosomes in almost all nuclei by the comma stage in N2 embryos, but many nuclei do not have
enrichment of H4K20me1 on the X chromosomes in comma stage and some 2-fold stagemes-2 MZ andmes-4 MZ embryos. (C) Quantiﬁcation of DPY-27-stained N2,
mes-2 MZ , and mes-4 MZ embryos. Each embryo was categorized based on the percent of its cells that demonstrated enrichment of DPY-27 on the X chromosomes.
(D) Quantiﬁcation of H4K20me1-stained N2, mes-2 MZ , and mes-4 MZ embryos. Scale bars equal 10 mm. Asterisks indicate level of statistical signiﬁcance (nPo0.05;
nnPo0.005; nnnPo0.001).
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the X chromosomes in mes mutant embryos by X-paint FISH
because MES-4 and H3K36me2 spread to the X chromosomes in
the absence of mes-2, 3, and 6 or are not detectable in the absence
of mes-4 (Bender et al., 2006). In mes-2, 3, and 4 MZ (lacking
both maternal and zygotic product) mutant embryos and embryos
from mes-6 RNAi-treated hermaphrodites, H4K16ac is no longer
depleted from the X chromosomes at early stages of development
(Fig. 5A). However, by the 2-fold stage, levels of H4K16ac are
reduced on the X chromosomes, resembling control embryos
(Fig. 5B). Like mutant hermaphrodite embryos, young male mes-
2 and mes-4 MZ embryos have similar levels of H4K16ac on
the X chromosome and autosomes (Fig. S4). After the 50-cell stage,
the levels of H4K16ac on the male X are equal to autosomal levels,
as in control embryos (Fig. S4). These data indicate that MES
function is necessary for the depletion of H4K16ac on X chromo-
somes in both hermaphrodite and male young embryos.
The timing of DC onset correlates with a loss of plasticity
C. elegans embryonic blastomeres begin to lose plasticity at the
onset of gastrulation, around the 30-cell stage (reviewed in
Maduro (2010)). One player in the transition from plasticity to
differentiation is MES-2 (Yuzyuk et al., 2009). Two clues hint that
differentiation signals the onset of DC in C. elegans. First, the DCC
localizes to the X during the window of development when
embryos transition to a differentiated state. Second, MES proteins
regulate both the chromatin state of the X during early embry-
ogenesis and the correct timing of differentiation onset. To test the
hypothesis that the transition from plasticity to differentiation has
a role in DC onset, we compared the timing of DCC localization to
the X chromosome in control and mes-2 MZ embryos. Asso-
ciation of the DCC component DPY-27 with the X chromosome
occurs between the 30-cell and 100-cell stages in wild type
embryos. In 24-cell embryos, DPY-27 is diffusely localized
throughout the nucleus. By the 50-cell stage, DPY-27 localizes to
the X chromosomes in more than half of the cells and appears as
punctate foci within nuclei. At the 100-cell stage, DPY-27 is found
on the X chromosomes in all cells (Fig. 6A and C). In mes-2
mutants, like wild type embryos, DPY-27 does not concentrate on
the X chromosomes at the 24-cell stage, indicating that DC onset is
not shifted earlier in these mutants (Fig. 6C). Furthermore, at the
50-cell stage, mes-2 mutants differ signiﬁcantly from wild type.
In the mutants, half of the embryos show punctate X-enrichment
of DPY-27 in less than half of their cells (compared to 23% in wild
type embryos). Only 6% of mutants show X-localized DPY-27 in all
cells (compared to 24% of N2 embryos). By the 100-cell stage, most
mes-2 mutant embryos resemble controls, and DPY-27 localizes to
the X chromosomes. We observed a similar delay in DCC localiza-
tion to X in mes-4 mutants (Fig. 6).
To address whether mes-2 affects other features of DC, we
examined the enrichment of H4K20me1 on the X chromosomes.
In wild type embryos, H4K20me1 is enriched on the X chromo-
somes in more than half of the cells in a comma stage embryo
(Fig. 6B and D). However, mes-2 mutant embryos are signiﬁcantly
delayed (Fig. 6B and D). This delay is evident in mes-2 mutants at
both the comma and 2-fold stages. A similar delay at the comma
Fig. 7. sdc-2 expression in mes-2(bn11) mutants. (A) Genetic pathway regulating SDC-2 expression and dosage compensation. (B) Analysis of gene expression of selected
dosage compensation genes from a previously published dataset (Yuzyuk et al., 2009). Solid lines indicate wild type embryos and dashed lines indicate mes-2(bn11) mutant
embryos.
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stage, but not the 2-fold stage, was observed with mes-4 mutant
embryos (Fig. 6B and D).
To determine whether this phenotype is solely due to lack of
maternal MES-2 protein (as opposed to zygotic expression), we
also examined heterozygous embryos (MZþ) descended from
homozygous mutantmes-2 mothers mated to wild type males. Our
statistical analysis showed that MZþ embryos were comparable
to MZ embryos, and both mutant genotypes were different
from wild type (Fig. S5). The difference is evident at the comma
stage, where MZ and MZþ embryos had signiﬁcantly more
cells still displaying diffuse nuclear staining. The difference
between the three genotypes at the 2-fold stage was not statisti-
cally signiﬁcant, possibly due to lower numbers of embryos in this
experiment.
To examine the mechanism of how MES-2 deﬁciency leads to
delayed DC onset, we analyzed publically available microarray data
for expression of DCC genes and regulators of the DCC in wild type
versus mes-2 mutants (Yuzyuk et al., 2009). Most DCC members
are maternally contributed to the oocyte and therefore are initially
present in both male and hermaphrodite embryos. By contrast,
SDC-2 is speciﬁcally expressed only in hermaphrodites between
the 30- and 50-cell stages, triggering both hermaphrodite devel-
opment (by repressing her-1) and initiation of dosage compensa-
tion (Dawes et al., 1999). Sex speciﬁcity of SDC-2 expression is in
turn regulated by XOL-1, which is regulated by X signal elements
(XSEs) and autosomal signal elements (ASEs) (Fig. 7A) (Meyer,
2010). A double-dose of XSEs counteracts the ASEs in hermaph-
rodites, leading to repression of XOL-1 and expression of SDC-2.
In males, a single XSE dose is unable to counterbalance the ASE
dose, leading to XOL-1 expression and repression of SDC-2.
Because most DCC genes are contributed maternally, expression
of these genes remains relatively constant from the 24-cell stage
through the 100-cell stage and does not differ between wild type
and mes-2 mutants (Fig. 7). As expected, SDC-2 expression
increases between the 50- and 100-cell stages in wild type
embryos, similar to other genes categorized as “Differentiation”
genes (Yuzyuk et al., 2009). However, expression of sdc-2 fails to
increase at the 100-cell stage in mes-2 mutants. Together, these
data indicate that the function of the MES proteins is required for
the proper timing of SDC-2 expression and, hence, DC onset. In
principle, a delay in SDC-2 expression could be due to misregula-
tion of the timing of expression of XSEs and ASEs or of a distinct
developmental regulator. However, XSE and ASE expression
appears largely unaffected in mes-2 mutants (Fig. S6). Although
we cannot exclude the possibility that the observed small differ-
ences in SEA-1 (an ASE) or SEX-1 (an XSE) (Fig. S6) account for the
delay in SDC-2 expression, we favor the possibility that a distinct
developmental regulator, under the control of MES-2, dictates the
timing of SDC-2 expression and dosage compensation.
Discussion
In this study, we show that the onset of dosage compensation is
linked to the loss of developmental plasticity in C. elegans
embryos. We establish a developmental timeline of chromatin
changes on the X chromosome before, during, and after this
developmental transition. In both male and female pregastrulation
embryos, the X chromosomes are depleted of H4K16ac dependent
on the activity of a PRC2-like complex. The DCC loads onto the
hermaphrodite X around the time of gastrulation, followed by the
appearance of H4K20me1 enrichment several cell cycles later. This
transition is delayed in mutant backgrounds in which embryonic
blastomeres display prolonged plasticity. Together with studies in
other systems, our results suggest that the onset of dosage
compensation may be universally linked to differentiation status.
Upregulation of the X chromosome
Upregulation of the X chromosome balances the monosomic X
to autosomes in males. This process in ﬂies is male-speciﬁc but is
thought to occur in both sexes in worms and mammals. Evidence
of X chromosome upregulation has been noted in mammals and
worms by both microarray and RNA-seq analyses (Deng et al.,
2011; Gupta et al., 2006; Kharchenko et al., 2011; Lin et al., 2007,
2011; Nguyen and Disteche, 2006). However, the mechanism that
governs upregulation is unknown. One possible mechanism could
involve changes in chromatin structure. H4K16ac promotes an
accessible chromatin environment and is associated with domains
of active transcription (Shogren-Knaak et al., 2006). H4K16ac is
also part of the X chromosome upregulation mechanism in male
ﬂies (Akhtar and Becker, 2000) and mammalian female cells (Deng
et al., 2013). Our data show no enrichment of H4K16ac on the X
chromosomes in early hermaphrodite, male, or DCC mutant
embryos. This result suggests either that the X chromosome is
not upregulated in early C. elegans embryos or that H4K16ac is not
a mechanism of global X chromosome upregulation in this organ-
ism. One possibility is that X upregulation occurs rapidly, just prior
to or concurrently with the DCC localization to the X chromosome.
Alternatively, X upregulation in worms may occur gene speciﬁcally
rather than chromosome-wide.
Stages of the establishment of dosage-compensated chromatin
In all systems studied, dosage compensation leads to the
establishment of a specialized chromatin environment, which
either enhances transcription (e.g., ﬂies), downregulates transcrip-
tion (e.g., worms), or turns off transcription (e.g., mammals).
In each case, establishment of dosage-compensated chromatin is
a multistep process.
Such a multistep progression has been well studied in mam-
mals (Morey and Avner, 2011; Nora and Heard, 2010). In undiffer-
entiated female mouse embryonic stem cells, both X chromosomes
are active and partially upregulated (Lin et al., 2007), and activat-
ing chromatin marks are uniform across the autosomes and both X
chromosomes. After differentiation is induced, Xist is expressed,
and after another 2 days, histone H4 becomes hypoacetylated on
the inactive X chromosome. A number of other chromatin changes
can also be observed soon after Xist coating, including the loss of
activating chromatin marks, such as H3K4 methylation and H3 and
H4 acetylation, and the increase in repressive chromatin marks,
such as H3K9me2, H3K27me3, and H4K20me1. Later steps in the X
inactivation process, which lock in the silent state, include incor-
poration of histone variant macroH2A and DNA methylation
(Morey and Avner, 2011; Nora and Heard, 2010). The process is
less well studied in male ﬂy embryos; however, evidence indicates
that establishment of dosage-compensated chromatin also
involves a multistep process. Localization of the MSL complex to
the X chromosome precedes accumulation of H4K16ac (Franke
et al., 1996). The length of time between MSL localization and
H4K16ac enrichment is undeﬁned, though it is likely to be at least
one cell cycle.
In this study, we report that the C. elegans X chromosome also
undergoes this transition in a stepwise manner. As in other
organisms, the ﬁrst step is the assembly of the DCC on the X
chromosome, which is initiated around the 30-cell stage (Dawes
et al., 1999). The timing when H4K16ac on the X chromosomes
transitions from a MES-regulated state to a DCC-regulated state is
difﬁcult to pinpoint exactly, but the transition occurs some time
after DCC loading. Our results, and those of others (Vielle et al.,
2012), demonstrate that H4K20me1 does not become X-enriched
until the bean and comma stages. Experiments using temperature-
sensitive alleles of dpy-27 and dpy-28 showed that the critical
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window for dosage compensation in development is around the
comma stage, the same timing as that of H4K20me1 enrichment
on the X chromosomes (Pleneﬁsch et al., 1989). One possible
scenario is that the DCC loads onto the X chromosomes around the
40-cell stage where it maintains repression of H4K16ac. Later,
enrichment of H4K20me1 solidiﬁes downregulation of the X
chromosomes at a time in development when certain X-linked
genes need to be downregulated.
Early embryonic development
One question raised by these studies is how undifferentiated
cells cope with the imbalance between the X and the autosomes.
In in vitro cultured undifferentiated female mouse embryonic
stem cells, the Xs are active but incompletely upregulated (Lin
et al., 2007). Perhaps the cells are able to tolerate this level of
imbalance. In vivo, the time window with two active X chromo-
somes in developing female embryos is relatively brief (Barakat
and Gribnau, 2012), again lessening the need for X chromosome
inactivation.
The situation seems somewhat different in C. elegans. In worms,
X-linked transcription may be limited in both male and hermaph-
rodite pregastrulation embryos, and therefore dosage compensa-
tion may not be necessary. The X chromosome is enriched for
“strictly embryonic” genes, which are not expressed in the germ-
line and tend to be turned on at or after the 40- to 60-cell stage
(Baugh et al., 2003). By contrast, germline-intrinsic genes and
sperm-speciﬁc genes are underrepresented on the X chromosome
(Reinke et al., 2000). In fact, few X-linked genes are expressed
during spermatogenesis and most of oogenesis, with the exception
of a burst of X-linked transcription in oocytes during late meiotic
prophase I (Kelly et al., 2002). Thus, the X chromosome has a
unique gene content, with fewer genes expressed in the germline
and early embryos than on autosomes.
In addition, the X chromosome in early embryos carries at least
some of the chromatin features established in the parents' germ-
line as an epigenetic memory of transcriptional activity (Arico
et al., 2011; Furuhashi et al., 2010; Rechtsteiner et al., 2010). The
role of the MES proteins in the germline is to repress expression of
somatic or ubiquitously expressed genes (including the majority of
X-linked genes) and to promote expression of germline genes
(Gaydos et al., 2012). Therefore, the X chromosomes in both sperm
and oocyte arrive with a limited transcriptional history and with a
relative lack of activating chromatin marks. This is particularly true
for the sperm-derived X (Xp), which remains silent throughout
spermatogenesis (Bean et al., 2004) (see also Fig. S1).
Whether the observed relative depletion of H4K16ac on the X
chromosomes of early embryos is due to the fact that fewer
X-linked genes are transcribed until the 40- to 60-cell stage, to
the inheritance of fewer activating chromatin marks due to X
repression in the germline, or to both is unclear. Alternatively, a
yet undeﬁned active mechanism may operate in early embryos to
speciﬁcally silence the X chromosome. In any case, the activity of
the MES proteins appears to be necessary for this depletion. In
wild type germlines, the X chromosome is strikingly depleted of
H4K16ac (Kelly et al., 2002). However, in the few remaining nuclei
in mes-3 and mes-6 MZ mutant germlines with desilenced X
chromosomes, the X gains H4K12ac (Fong et al., 2002). Here we
have shown that the X chromosomes in mes mutant embryos have
increased levels of H4K16ac compared to wild type, suggesting
that the mutants retain the germline desilenced chromatin state.
Do these changes in H4K16ac reﬂect changes in gene expres-
sion? Microarray analysis of gene expression in mes-2 mutant
embryos did not show a preference for upregulation of X-linked
genes (Yuzyuk et al., 2009). Even when the analysis is limited
to “strictly embryonic genes,” the difference in gene expression
changes on the X chromosome compared to autosomes is not
statistically signiﬁcant (Wells MB, G. Csankovszki, unpublished
analysis). Gene expression studies in mes mutant germlines
revealed a similar scenario (Gaydos et al., 2012). In mes-2 or
mes-4 single mutants, a bias towards upregulation of X-linked
genes was only modest. However, this bias became more pro-
nounced in the mes-2; mes-4 double mutants (Gaydos et al., 2012).
A bias towards upregulation of X-linked genes may become
apparent in embryos depleted of both MES-2 and MES-4.
Linking dosage compensation to differentiation and the role of PRC2
Dosage compensation in mammals involves two steps. The ﬁrst
is upregulation of the X chromosome in both males and females,
which balances the X to autosomes in males. The second step is
inactivation of one of two X chromosomes in females to prevent
overexpression of X-linked genes. While the ﬁrst step is initiated
in undifferentiated cells (Lin et al., 2007), the second step appears
to be linked to the onset of differentiation in a variety of settings
(Barakat and Gribnau, 2012). These settings include in vivo differ-
entiation of cells during development (Monk and Harper, 1979)
and in vitro differentiation of embryonic stem cells (Rastan and
Robertson, 1985). Conversely, X chromosome inactivation is
reversed in vivo during the development of female primordial
germ cells (Monk and McLaren, 1981) and in vitro during repro-
gramming of female somatic cells (Maherali et al., 2007). Thus, X
chromosome inactivation and pluripotency are intimately linked.
This coupling is achieved by direct regulation of Xist, and its
antisense regulator Tsix, by pluripotency factors (Barakat et al.,
2011; Navarro et al., 2008, 2010; Nesterova et al., 2011).
In C. elegans embryos, the timely onset of differentiation and
the timing of DC onset are regulated by PRC2 ((Yuzyuk et al., 2009)
and this study). Consistent with late DC onset, C. elegans embryos
lacking MES-2 exhibit a delay in the expression of SDC-2, the
hermaphrodite-speciﬁc DCC component whose expression trig-
gers DCC assembly on the X chromosome. What causes this delay
in expression is unclear, but possibilities include prolonged
expression of an SDC-2 repressor or delayed expression of an
SDC-2 activator.
In mammals, Polycomb complexes regulate cell fate transitions
in ES cells (Surface et al., 2010). PRC2 proteins bind and repress
master developmental regulators in undifferentiated mammalian
ES cells, and this result suggests that Polycomb maintains plur-
ipotency by repressing these developmental regulators (Boyer
et al., 2006; Lee et al., 2006). In accordance with this prediction,
Eed null ES cells have increased expression of differentiation genes
and a strong propensity to differentiate (Boyer et al., 2006).
However, pluripotency is maintained in the absence of PRC2
(Chamberlain et al., 2008; Pasini et al., 2007). The balance between
pluripotency and differentiation is maintained by a PRC2 complex
in mammalian ES cells that contains the Jarid2 protein (Landeira
et al., 2010; Pasini et al., 2010; Peng et al., 2009). In the absence or
depletion of Jarid2, the expression of differentiation genes and
in vitro differentiation are delayed (Li et al., 2010; Shen et al.,
2009). Therefore, the lack of various PRC2 components appears to
cause both continued expression of pluripotency factors and
aberrant expression of developmental regulators.
This phenotype is similar to that shown for PRC2-deﬁcient
C. elegans embryos. Overall, mes-2 mutant embryos exhibit a delay
in loss of pluripotency (Yuzyuk et al., 2009). Additional studies
have suggested that the MES proteins regulate expression of
developmental regulators at the appropriate time. In the germline,
absence of the mes genes makes germline cells susceptible to
conversion into differentiated somatic cells upon expression of
regulatory genes (Patel et al., 2012). In the germline, the MES
proteins appear to repress somatic genes (Gaydos et al., 2012).
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Whether the C. elegans PRC2-like complex regulates pluripotency
factors remains unknown.
In summary, our results are consistent with the hypothesis that
dosage compensation onset is regulated by the transition from a
plastic state to a differentiated state. This study demonstrates that
the regulation of DC onset by the loss of plasticity is a conserved
feature across two different mechanisms of DC. Future studies will
examine those factors that directly contribute to the regulation of
the onset of embryonic expression of DCC components, such as
sdc-2.
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